

A Coherent Analytical Review of Indapamide

A. P. Rajput^{1*} and A. P. Edlabadkar²

¹K. K. Wagh Arts, Commerce, Science & Computer Science College, Nashik - 422003, India

²Z.B. Patil Arts, Science and Commerce College, Deopur, Dhule (MS) - 424002, India

*aprajput@rediffmail.com (Corresponding Author)

ARTICLE INFORMATION

Received: July 20, 2021

Revised: September 27, 2021

Accepted: October 15, 2021

Published Online: May 07, 2022

Keywords:

Indapamide, Diuretic, Pharmaceutical Analytical Profile, Review



DOI: [10.15415/jptrm.2022.101004](https://doi.org/10.15415/jptrm.2022.101004)

ABSTRACT

Background: Indapamide is a diuretic of particular importance in an antihypertensive therapeutic regime that is profoundly applied to treat hypertension. Besides using as an individual drug for its diuretic and thereby antihypertensive effect, the drug is also a part of crucial combinations with Angiotensin-Converting Enzyme inhibitors. The recent combinations of Indapamide with Perindopril and Delapril work as the best therapies for heart patients.

Purpose: Considering the therapeutic and pharmaceutical importance of the drug molecule and its potential to be explored in future drug discovery and delivery, we made efforts to portray the pharmaceutical analytical profile of the drug molecule at ease.

Method: The present article is a composition entailing the comparative and critical evaluation of the various analytical approaches explored for the pharmaceutical estimation of Indapamide as a particular drug in combinations and pharmaceutical as well as biological matrices. The analyses are reviewed for the specific applications of analytical methods tested Indapamide alone or with other medications.

Result: The anticipated study revealed the comparative usage of different research techniques for Indapamide estimation. The study influences the possibility of constraints and focuses on the recent trend in Indapamide analysis. The article also provides an understanding of sample processing, drug extraction method, validation protocols/approaches, and stability studies, including but not limited to the bioanalytical perspectives.

Conclusion: This review can be explored thoroughly for the future analytical and pharmaceutical insights of Indapamide to the fullest.

1. Introduction

Indapamide (IND) is a diuretic resembling thiazide, and it is 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoyl-benzamide a thiazide-like drug recognized to manage hypertension, as well as decompensate heart failure [Budavari 1996, Bataillard 1999]. The molecular structure of IND is presented in (Figure 1). High blood pressure is being effectively managed using IND. It also reduces excessive body fluid (edema) about heart failure. Decreasing high BP aids stroke prevention and the possibility of heart attacks and kidney problems. Diuretics or water pills are the class for which IND is well known [Ernst 2022].

IND alone or in a mixture with other drugs used to manage hypertension [Waeber 2003]. IND is available in combination with Perindopril, an Angiotensin Converting Enzyme (ACE) inhibitor. Diuretics like thiazide (IND and chlorthalidone) are more effective in lowering the

risk of cardiac disease in individuals facing elevated blood pressure than those used with thiazide diuretics (including hydrochlorothiazide). The adverse effect levels are thiazide-like, and thiazide-type diuretics are almost identical. It was patented in 1968 and approved for therapeutic purposes in 1977 [Asmar 2001]. IND is also available in combination with Atenolol [Divity 1983], Amlodipine [Jadhav *et al* 2014], and Delapril [Cavalieri 2007].




Figure 1: Chemical structure of Indapamide.

2. Pharmacopoeial Insight

The IND is official as an Antihypertensive drug in the IP (Indian Pharmacopoeia) [IP 2018], BP (British Pharmacopoeia) [BP 2022], and USP (United States Pharmacopoeia) [USP 2018].

3. Indian Pharmacopoeia (IP)

IP depicts the reports for HPLC (High-Performance Liquid-Chromatography) IND analysis. For the effective resolution of IND stainless steel column (15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 μ m) was implemented. The solvent system comprises 6 volumes of a solution containing sodium dodecyl sulfate (5% w/v) and glacial acetic acid (3% v/v), 10 volumes of triethylamine, 20 volumes of 2-butanol, 310 volumes of acetonitrile and 690 volumes of water, followed by the adjusting of the pH to 3.0 using orthophosphoric acid. The rate of flow of solvent system was kept at 1.6 ml/minute and monitored at 240 nm [IP 2018].

4. British Pharmacopoeia (BP)

BP has presented on HPLC procedure for the investigation of IND. The separation of the IND has been attained on column (0.15 m long and 4.6 mm wide, packed with octadecylsilyl silica gel for chromatography R (5 μ m). The acetonitrile R (7 volumes) with tetrahydrofuran R (20 volumes) and 1.5 g/l solutions of trimethylamine R (73 volumes) were adjusted to 2.8 pH with phosphoric acid. The mixture was employed as a solvent system and the rate of flow of solvent system was tuned to 1.4 mL/min. The IND was identified at a wavelength of 305 nanometers. [BP 2022].

5. United States Pharmacopoeia [USP]

USP stated reports HPLC procedure for the assay of IND at 242 nm. The separation of the IND along with internal standard 2'-chloroacetophenone has been executed on a stainless-steel column (4.5 mm x 10 cm) containing a 3 μ m packing of octadecylsilane. The solvent system composed of a blend of sodium 1-octanesulphonate (1.08 gm) in 700 ml water with 10 mL of glacial acetic acid and 300 mL (acetonitrile), and the flow rate was tuned to 1.0 mL per minute [USP 2018].

5.1. The Merck index

Revealed information regarding the physical properties and solubility of IND. The reports displayed that IND is a white coloured powder drug practically insoluble in water, soluble in alcohol, and slightly soluble in ether. The drug is light sensitive and needs to be protected from light [Budavari 1996].

6. Performance Review on Analytical Techniques Implemented for IND

For assessing IND both in the pharmaceutical matrix and in bio-samples, a range of separation methods includes HPLC, LC-MS/MS, HPTLC, and Spectrophotometric have been studied.

6.1. HPLC Methods

The appreciable explored analytical technique implemented for the determination of IND is HPLC. The exploratory report on the HPLC methods for studies was compiled in Table 1.

Table 1: HPLC methods for analysis of IND.

Sr. No.	Analytes	Matrix	Chromatographic condition	Mobile Phase	Retention Time and Detection Wavelength,	Flow rate Injection volume	Ref.
1.	ATN and IND	Tablet	(Hypersil Gold: 250mm x 4.6 mm, 5 μ m)	0.1% Triethyl Amine in water of pH 3.0 & Methanol in the ratio 30:70 v/v	3.05 and 3.93 min, 240 nm	1.0 ml/min, 20 μ l	Arindam Basu et al. 2011
2.	ATN and IND	Tablet	Hypersil BDS C18 (250 mm x 4.6 mm, 5 μ m particle)	(pH = 3.5, 0.01 M potassium dihydrogen orthophosphate buffer-acetonitrile (60:40; v:v)	5min, 231 nm	1.0 ml/min, 20 μ l	Thulasamma Parusu & Venkateswarlu Ponneri 2012
	Milk						
	Human Blood						

3.	PDP and IND	Tablet	C18 (125 mm×4.0 mm i.d., with a particle size of 5 µm)	Acetonitrile, methanol and phosphate buffer of pH 3.0 (50:3:47V/V/V)	2.9 and 4.6 min, 210 nm	0.7 ml/min, 20 µl	Anna gumieniczek et al. 2015
4.	ATN and IND	Tablet	C18 (250×4.6 mm 5 µm, I.D)	Methanol: water (adjusted to pH 2.7 with 1% ortho phosphoric acid) 80:20v/v	1.766 min & 3.407, 230 nm	1.0 ml/min, 20 µl	G.tulja rani et al. 2011
5.	PDE and IND	Bulk	Zorbax SB C18 Rapid Resolution (150 mm X 4.5 mm) column with 3.5 µm particle size	(Phosphate buffer:ACN52:48 V/V)	1.93 & 3.17, 210 nm	1.0 ml/min, 5 µl	Ion Valen et al. 2015
6.	IND	Racemic Mixture	(150 x 4.6 mm, 5 µm)	Na ₂ HPO ₄ 10 mM buffer, ACN (95:5)	5.5 & 7.09 242 nm	1.0 ml/min, 5 µl	Ancagabrielacârje et al. 2016
7.	IND	Tablet	C18 (250 mm × 4.6 mm, 5 µm)	Na ₂ EDTA 0.2 g/L and anhydrous acetic acid 0.1 mL/L, Acetonitrile and Methanol (65:17.5 :17.5: 1.2) (V/V/V/V)	16.92, 254 nm	1.-1.3 ml/min, 10 µl	Simonacodruţahegheş et al. 2017
8.	IND	Human Blood	C18 (15 cm x 4.6 mm I.D.x 5 µm)	80 mM ammonium acetate, pH 3.5 (adjusted with concentrated hydrochloric acid acetonitrile-2-propanol (65:30:5, v/v/v)	5.2 & 241 nm	1.0 ml/min, 40 µl	R. Brent Miller et al. 1993
9.	OSM and IND	Bulk and Tablet	C18 AR column (250 × 4.6 mm id, 5 µm particle size)	Sodium perchlorate and triethylamine buffer solution (at pH 3): Acetonitrile (60:40 v/v)	6.8 & 5.3, 280 nm	1.0 ml/min, 10 µl	AvaniSheth et al. 2013
10.	PDA and AMD and IND	Bulk and Tablet	BDS Hypersil C18 column (100 × 3 mm, 5 µm)	0.05 M potassium dihydrogen phosphate buffer (pH 2.6)–methanol (50 and 50, v/v	3.4, 6.0, 2.0 & 215 nm	0.6 ml/min, 100 µl	Ramzia I. El-Bagary et al. 2015
11.	CP and IND	Bulk and Tablet	250 X4.6mm terra RP8 column, 5µm	26mM pentane-1-sulfonic acid sodium salt in 30mM potassium dihydrogen phosphate (pH 2.8, adjusted by phosphoric acid):methanol: acetonitrile (6:2:2 v/v/v).	1.8, 1.3min 210 nm	2.0 ml/min, 20 µl	Alaa El-Gindy et al 2014

12.	PERI and IND	Bulk and Tablet	RP-YMC pack ODS A-132 C18 (5 µm, 15 cm×6.0 mm i.d.) column.	phosphate buffer pH 2.4 and acetonitrile (7:3 v/v)	5.8 min 215 nm	1.0 ml/min, 20 µl	NevinErk et al 2001
13.	ATL and IND	Bulk and Tablet	C18 column	methanol: water (60:40) with 0.1%v/v of Ammonium Hydroxide	7.5 and 8.9 min 260 nm	1.0 ml/min, 20 µl	Naveen Kadian et al 2012
14.	ATL and IND	Bulk and Tablet	Symmetry X-terra C8 (4.6mm x 100mm, 5µm) column	Potassium di hydrogen phosphate buffer and Acetonitrile in the ratio 40:60 v/v	2.1 and 3.6 min 240 nm	1.0 ml/min, 20 µl	K Madhavi et al (2014)
15.	LIS and IND	Bulk and Capsule	C18 column	methanol:water (50:50, v/v)	4.71±0.2 18.51±0.3, 206nm	1.0 ml/min, 100 µl	Sofia Negro et al (2014)
16.	PERI and IND	Bulk and Tablet	C-18 column (150mm x 4.6mm, 5µm	acetonitrile: 5mM sodium phosphate buffer (pH 7.5) (50:50)	2.5 and 4.7 min 202 nm	1.0 ml/min, 20 µl	Menna I. Ezzeldina et al (2013)
17.	AML and IND	Bulk and Tablet	C18 Column	Acetonitrile: Water contains 0.2% of Triethyl amine and adjusting the pH to 4.0 with orthophosphoric acid (70:30, v/v, pH 4.0)	3.27 and 4.7 min 238 nm	0.8 ml/min, 20 µl	Mehul M. Patel et al (2012)
18.	AML and IND	Bulk and Tablet	Brownlee C-18	0.02 M potassium dihydrogen phosphate– methanol (30: 70, v/v)	5.9 min and 3.6 min 242 nm	1.0 ml/min, 20 µl	Deval B. PATEL et al (2012)
19.	IND	Rat whole blood	Chromosil ODS column(250 × 4.6 mm id, 5 µm particle size)	methanol–acetonitrile–tetrahydrofuran–0.2% trifluoroacetic acid (170:20:15:38, v/v/v/v)	2.1 and 3.6 min 240 nm	0.8 ml/min, 20 µl	XubinSuo et al (2013)
20.	PERI and IND	Bulk and Tablet	BDS hypersil C18 column (25cm×4.6mm, 5)	potassium dihydrogen phosphate buffer (pH 2.6) and acetonitrile (65:35, v/v)	210 nm	1.5 ml/min, 10 µl	A.K. Pathak et al (2011)
21.	PERI and IND	Bulk and Tablet	Kromosil C18 column (250×4.6mm× 5µ	Phosphate buffer: ACN: methanol (40:25:35 v/v/v) pH 4.5	2.350 and 3.490 min 223 nm	1.0 ml/min, 20 µl	S. Soujanya (2017)
22.	IND	Bulk and Tablet	LiChrospher RP- 18 column	acetonitrile-distilled water (35: 65)	8.25-8.30 min 254 nm	1.5 ml/min, 20 µl	TUNCCEL OZDEN et al (1998)

23.	PERI and IND	Bulk and Tablet	BEH C18 (1.7 μ m, 2.1x50 mm)	0.01% v/v formic acid in water adjusted to pH 4 with acetic acid and acetonitrile (40:60 v/v)	4.5 min 227 nm	0.3 ml/min, 1 μ l	Naser F. Al-Tannak et al (2018)
24.	HCTZ and IND	Bulk drug and Tablet	Hypersil-Gold C18 (100 \times 4.6 mm, 3 μ m)	58% buffer (5 mM KH ₂ PO ₄ , containing triethylamine 0.25 ml/L), 25% acetonitrile and 17% methanol (pH adjusted to 2.8 \pm 0.1)	3.4 and 6.6 min 215 nm.	1.0 ml/min, 10 μ l	Ashok K. Shakya et al (2014)
25.	AML and IND	Bulk and Tablet	C-18 ODS bonded column (25cm \times 4.60 mm, 10 μ l)	methanol: water (95:5 % v/v)	8.780 and 2.850 min, 238 nm	1.0 ml/min, 10 μ l	VarshaKashaw et al (2016)
26.	IND	Bulk and Tablet	RP C-18 Column (25cm \times 4.6 mm i.d., 5 μ m)	o-phosphoric acid (0.05%) buffer of pH 3.0 and Acetonitrile in the ratio of 60:40 (v/v)	6.76 \pm 0.0145 min 240 nm.	1.0 ml/min, 20 μ l	Sathish Kumar Shetty A. et al (2011)
27.	IND	Human Whole Blood	YMC ODS-A reverse column (5 μ m particle size, 4.6-150 mm i.d.)	Acetonitrile - 2-propanol)0.1 triethylamine in water (adjusting to pH 3.75 with 85% phosphoric acid) (35:5:60, v/v/v).	12 min, 240 nm	1.2 ml/min, 20 μ l	Xinguo Jiang et al (2005)
28.	AML and IND	Bulk drug and Tablet	ODS (C18), 250 mm \times 4.6 mm & 5 μ m	Phosphate buffer (pH 4.0): Acetonitrile (40:60 v/v)	3.5 min and 4.8 min, 247 nm	1.0 ml/min, 20 μ l	G.V.S. Kumar et al (2012)
29.	AML and IND	Bulk and Tablet	C18 column (Phenomenex C18, 5 μ , 250 mm \times 4.6 mm)	Methanol: Water in the ratio of (95:5 v/v)	8.722 and 2.855 min 238 nm	1.0 ml/min, 20 μ l	Manish C. Raj et al (2012)

IND in a mixture with other drugs is also available in the market. The detailed account of HPLC analysis for IND in combination with other medications is as follows;

Basu A. *et al.* established the HPLC analysis for the parallel quantification of Atenolol (ATL) and IND tablet dosage and validated the method. The systematic separation of analytes was accomplished on the L1 Hypersil Gold column (250 \times 4.6 mm and particle size 5 μ m) flushed with methanol: water (70:30 % v/v) as a solvent system. The pH was acclimatized to 3.0 using triethylamine (0.1%). The system was run in an isocratic mode of elution. The detection was performed wavelength of 240nm. ATL and IND, Rt (retention time) were reported at 3.05 and 3.93 min, correspondingly. The approach has been tested successfully within harmony for specificity, precision, robustness, and accuracy. The studied approach was effectively explored for the tablet formulation [Basu 2011].

Valentin *et al.* illustrated HPLC and CZE to study and separate Perindopril Erbumine (PER) and IND. The resolution of selection candidates was achieved on a C18 Zorbax SB column having a particle size of 3.5 μ m. The rational separation was executed using a solvent system comprised of potassium dihydrogen phosphate buffer of pH 2.8 (5 mM) and ACN (52:48 %v/v). The estimation of the drug was performed at 215 nm. The electrophoretic migration was governed by ideal conditions such as borate buffer (50 mM) having a pH (9.2). The voltage applied was 25kV; whereas, the capillary temperature was monitored at 25°C. The injection was performed at 30 mbar - 3 seconds. For both these methods, the total run duration was less than 5 min. The LOD and LOQ values for PER and IND were established (2 μ g, 200 μ g, 0.4 μ g; 25 μ g and 4 μ g, 250 μ g, 4 μ g, 50 μ g), respectively, for HPLC and CZE. [Valentin 2015].

An RP-HPLC protocol was studied and tested for validation for quantification of Amlodipine (AML), IND, and PER, alone and in pharmaceutical preparation by El-Bagary, R.I. *et al.* A C₁₈ column of BDS Hypersil (100 3 mm, 5 µm) was exploited for effective separation. The analysis was executed using a solvent system comprising 0.05 M (potassium dihydrogen phosphate buffer; pH 2.6) and methanol in the proportion (50:50 % *v/v*) at 0.6 mL/min and isocratic elution was reported. Further, the column temperature was monitored at 50°C. A 100 µL solution was injected as a sample and detected at a wavelength of 215 nm. The IND calibration plot was studied in the range of 0.5 - 20 µg/mL concentrations.

The study has also acknowledged that the method currently developed has been systematically correlated with standard approaches. The accuracy outcome was identified to be 99.53-102 % for PER, 98.13-101.08 % for AML, and 98.00-101.43 % for IND [El-Bagary 2017].

Madhavi K. *et al.* have explained a simple reversed-phase-HPLC method for concurrently assessing ATL and IND in the pharmaceutical matrix. The separation of the analyte was achieved on the Symmetry X-terra C8 column with specifications as 5 µm (particle size) and (4.6 mm 100 mm) and a solvent system comprised of (60:40% *v/v*) at 0.7 mL/min rate of flow) acetonitrile and potassium dihydrogen phosphate. The effective identification was made at 240 nm using a UV detector. The linearity study was calculated by plotting the linearity in the concentration range of 1-5 µg/mL (IND) and 20-100 µg/mL (ATL). For ATL and IND, the limit of detection and quantification was found to be 0.22, 0.67, and 0.28, 0.86 µg, correspondingly. The reported protocol was also treated to estimate analytes in a marketed pharmaceutical formulation. The determining drug content was 100.20 % for ATL and 99.11 % for IND, respectively [Madhavi 2014].

Ezzeldin, M.I. *et al.* Documented HPLC and spectrophotometric methods for the real-time estimation of PER and IND in bulk powder and the tablets matrix. The effective separation of the drug candidate has been done on an Econosphere C18 column (150 4.6 mm, particle size 5 µm) comprising acetonitrile: 5 mM sodium phosphate buffer (pH 7.5) in the proportion of 50:50 % *v/v* as a solvent system. The detection was done using a UV detector at a wavelength of 202 nm when the flow rate (0.5 mL/min) was adjusted.

Two methods, the ratio subtraction, and the first derivatives, were used in respect of the spectrophotometric techniques. In the method of ratio subtraction, absorbance readings were taken in methanol at two wavelengths of 277.48 nm (ALK, λ max) and 315 nm (HTZ extended-spectrum).

The subtraction proportion technique implemented the two wavelengths, 277.48 nm and 315 nm (extended-

spectrum), to get absorbance. The solvent used was methanol. The area around the wavelengths 237.2 nm (for ALK) and 275.8 nm (for HTZ) was employed. The proposed method was tested for validation as per the guidelines of ICH Q2 (R1) [Ezzeldin 2013].

The specific high-performance liquid chromatography technique for estimating IND in the pharmaceutical matrix on the Turkish market has been developed by Ozden, T. *et al.*

The investigation was performed on LiChrospher C18 column and acetonitrile and distilled water (35:65 % *v/v*) as a solvent system, and the flow rate (1.5 mL/min) was adjusted. The detection at 254 nm using a UV detector was done. The retention time was 8-9 minutes, and the total retention time was under 10 minutes [Ozden 1998].

Al-Tannak, N. F., has developed UHPL-UV methods for the simultaneous analysis of PER and IND in a tablet dosage form and validated for stability.

A BEH C18 column (50 2.1 mm, 1.7 µm) was used for the estimation using a mobile phase consisting of water (0.01 % formic acid) and acetonitrile in a ratio of 40:60 % *v/v*, and the pH was kept at 4.0 using acetic acid. In total, the run time was reported to be below 5 min. The wavelength of measurement was 227 nm. The product samples were also subject to different stresses such as acidic, basic, and thermal.

Besides, UHPLC-Quadrupole time for Flight-Mass spectrometry (UHPLC-QToF-MS) has elucidated the degradation products of the combination [Al-Tannak 2018].

Dawud, E.R., and Shakya, A.K. notified an accurate and HPLC method for the simultaneous estimation of ACE inhibitors with HCTZ and IND in pharmaceutical formulations.

The Design of Experiments, specifically central composite design, had successfully implemented for method development and optimization [Dawud 2019].

Mahant, B.D. *et al.* have validated UV-spectrophotometric and stability-indicating RP-HPLC procedure for quantifying AML and IND simultaneously in combined tablets in the presence of degradation products generated from stress degradation studies.

The measurement of absorbance was observed for the simultaneous equation method. The method relies upon the two wavelengths; 237 nm (λ max AML) and 242 nm (λ max IND). The drugs obeyed Beer's-Lambert's law on a scale of 5-25 µg/mL and 1-11 µg/mL, respectively. The correlation coefficient obtained was 0.99 for AML and 0.99 for IND [Mahant 2016].

6.2. Spectrophotometric method

Spectrophotometric methods with UV-Visible detection have been studied for IND analysis with or without combination, as illustrated in (Table 2).

Table 2: UV-Spectrophotometric methods for determination of IND.

Sr. No.	Drug	Method	Matrix	Linearity ($\mu\text{g/ml}$)	Ref.
	IND on condensation with p-dimethylaminocinnamaldehyde (PDAC) and p-dimethylaminobenzaldehyde (PDAB)	Area Under Curve 682.0nm and 602.0nm	Bulk and Tablet	6-16 $\mu\text{g/ml}$, 50-250 $\mu\text{g/ml}$ and 1-18 $\mu\text{g/ml}$	Jyoti B. Pai et al (2011)
	ATL and IND	Simultaneous 266 nm and 270.2 nm UV	Bulk and Tablet	100-350 and 5-17.5 $\mu\text{g/mL}$	N. Fernandes et al (2008)
	AML and IND	First-Order Derivative UV Spectrophotometry 242 and 238 nm Absorption Correction Method	Bulk and Tablet	10-70 $\mu\text{g/ml}$ and 2-16 $\mu\text{g/ml}$	Mehul M. Patel et al (2012)
	Aceclofenac and IND	642.6 nm 783.2 nm	Bulk and complex	80-160 $\mu\text{g/ml}$	Singhavi et al (2007)
	IND	Two derivative spectrophotometric 252.8 nm and 260.4 nm	Bulk and Tablet	1-30 $\mu\text{g/mL}$ and 1-35 $\mu\text{g/mL}$	SacideAltinoz et al (2002)
	TEL and IND	Simultaneous 295 nm and 239 nm	Bulk and Capsule	2-10 $\mu\text{g/ml}$ and 2-14 $\mu\text{g/ml}$	Purvash K Patel et al (2012)
	PERI and IND	Simultaneous 210.4nm and 241.2nm	Bulk and Tablet	24 – 56 $\mu\text{g/mL}$ and 7.5 – 17.5 $\mu\text{g/mL}$	Darshana K. Modi et al (2011)
	IND	Simple UV 240 nm and 223 nm	Bulk and tablet	5 –40 $\mu\text{g/ml}$	TarkaseKailash N et al (2012)
	TEL and IND	Simultaneous and Q-Absorption Ratio Method	Bulk and tablet	4-14 $\mu\text{g/ml}$	J.M. Chavda et al (2012)

The UV-method for evaluating IND in bulk and pharmaceutical formulation was reported by **Pai, J. B. et al.** IND yields bottle-green and blue coloured complex when it condenses with p-dimethylaminobenzaldehyde (PDAB) and p-dimethylaminocinnamaldehyde (PDAC) in an acidic media. Methods A, B, and C used Area Under Curve (AUC) for the assessment of IND in the range of wavelength (238 - 248 nm [Pai 2011].

ATL and IND in their combined dose form have been simultaneously determined using a UV spectroscopic technique, which has been tested by Fernandes, N., and co-workers. In the first method, two wavelengths 246.4 nm and 266 nm are analyzed as potential candidates for establishing simultaneous equations. The use of two wavelengths to create a situation in which the absorbance variation kept zero for the other drug was the basis behind the second concept. Anequal absorbance was found at 246.4 nm and 254.2 nm for ATL. Subsequently, the absorbance variability was monitored in order to estimate the IND.

ATL determination was evaluated at 266 nm and 270.2 nm as well [Fernandes 2008].

Shah, R.N., and colleagues have studied UV-Spectrophotometry for the assessment of AML and the IND in tablets. The first approach was the absorption correction which needed a direct determination of AML at 360 nm. Because at this wavelength, zero absorbance was found for IND and the drug exhibited no visible disruption. For the determination of IND, the corrected absorbance was determined wavelength of 242 nm due to the intervention of AML at this wavelength. First-order derivative spectrophotometry was the method under study in the second section. The wavelengths chosen for the measurements were 238 nm for IND and 242 nm for AML (zero-crossing point for IND) (zero-crossing point for AML) [Shah 2012].

Patel, P. K. et al. investigated the rapid and economical spectrophotometric procedure for telmisartan (TEL) and IND in a pure and combined matrix. The simultaneous

equations method implements two wavelengths, 295 nm, and 239 nm, as absorbance maxima (λ_{max}) for TEL and IND, respectively. The analysis was performed using methanol-distilled water mixture [Patel 2012].

Chavda, J.M. *et al.* studied the two methods, by UV-Spectrophotometric tool for analysis of TEL and IND present in combined matrix [Chavda 2012].

7. High-Performance Thin-Layer Chromatography (HPTLC)

HPTLC exploration has been briefed for IND analysis alone or in the combined dosage form, as depicted in (Table 3).

Nazareth, C., and co-authors established the procedure for the measurement of Olmesartan (OLM) and IND in their combined formulation. The method has been tested for validation parameters *viz* accuracy, precision, specificity, and robustness under ICH guidelines [Nazareth 2013].

Vyas, N *et al.* studied the accurate and reliable high-performance thin-layer chromatography procedure for simultaneously determining Nebivolol (NEB) and IND in pharmaceutical formulation. The method has been studied on silica gel 60 F₂₅₄ thin layer chromatography foil and validated as per the ICH guidelines [Vyas 2012].

Bhoirand co-workers have explored the HPTLC approach, which depends on separating two drugs on plates of aluminium-backed pre-coated silica gel 60F₂₅₄. The customized operational conditions gave a compact spot for PER and IND at retention factor (R_f) 0.30 ± 0.02 and 0.60 ± 0.02 , respectively [Bhoir 2014].

Patel, N.M. *et al.* demonstrated a new stability-indicating HPTLC approach for assessment of TEL and IND simultaneously in the presence of their degradation material and in their marketed matrix. In the stationary phase, the procedure was performed on aluminium-backed thin-layer chromatography foil (silica Gel 60F₂₅₄) [Patel 2013].

Table 3: Overview on HPTLC methods for quantification of IND.

Sr. No.	Drugs	Matrix	Stationary phase plates	Mobile phase Composition	Linearity (ng/spot)	Rf	Ref
1.	OML and IND	Bulk drug and Tablet	Silica gel 60 F254	Toluene: Chloroform: Ethanol (4:4:1 v/v)	100 to 700 ng/spot and 100 to 600 ng/spot	0.15 and 0.47	Celina Nazareth et al (2013)
2.	NEB and IND	Bulk drug and Tablet	Silica gel 60 F254	Ethyl acetate: methanol: dil. ammonia, (8.5: 0.8: 1.0 v/v/v)	500–4000 ng /spot and 300–1050 ng/spot	0.43 and 0.64	Niraj Vyas et al (2012)
3.	ATL and IND	Bulk drug and Tablet	Silica gel 60F254	Toluene: ethyl acetate: methanol: ammonia 5:3:3:0.1 (v/v/v/v)	200-1200 ng/spot and 100-600 ng/spot	0.27 and 0.71	Janhavi R Rao et al (2011)
4.	AML and IND	Bulk drug and Tablet	Silica gel 60F254	Dichloromethane: methanol: ammonia 8.5: 1.5: 0.1 (v/v/v)	300-1500 ng/spot and 100-500 ng/spot	0.3 and 0.8	A.K. Desai et al (2012)
5.	PERI and IND	Bulk drug and Tablet	Silica gel 60 F254	Dichloromethane: Methanol: Glacial acetic acid in the ratio of 9.5:0.5:0.1 (v/v/v)	1000-5000 ng/ band and 200-1000 ng/band	0.30 and 0.60	Mrinalini C. Damle et al (2014)
6.	TEL and IND	Bulk drug and Tablet	Silica Gel 60F254	Toluene: Ethyl Acetate: Acetone: Methanol (7: 4: 3: 1, v/v/v/v)	30-1000ng/spot and 600-200 ng/spot	0.61 and 0.34	RavalManan A. et al (2013)

8. Hyphenated Approaches

The HPLC coupling with an MS or MS-MS is a highly responsive hyphenation. Such coupling can be used to analyze the multiple components. Later, to examine the

specificity of analysis, it is the most credible to examine active pharmaceutical ingredients from samples of biological origin. A sample's ionization was followed by an LC/MS/MS technique for IND analysis. It was carried out as API, separated from the mass analyzer's high vacuum. Two

widely used procedures for the examination are atmospheric pressure chemical ionization (APCI) and electrospray ionization (ESI). The different phases of mass analysis are

involved in tandem-mass spectrometry (MS/MS). The speculations are presented in (Table 4).

Table 4: LC-MS/MS protocols for measurement of IND.

Sr. No.	Drugs	Matrix	Extraction method	m/z ratio	References
1.	IND	Human serum	SPE	366	Natalija Nakov et al (2013)
2.	IND	Human serum	SPE	364	Jingling Tang et al (2005)
3.	IND	Human plasma	liquid-liquid extraction	364	Lin Xie et al (2006)
4.	IND	Human plasma	liquid-liquid extraction	364.3	Li Ding et al (2006)
5.	IND	human whole blood	liquid-liquid extraction	366.10	Deepak S. Jain et al (2006)
6.	IND	human serum	SPE	366	Hideyuki Morihisa et al (2008)
7.	Beta blockers	Human urine	SPE	–	Gordon J. Murray et al (2009)
8.	IND	human whole blood	SPE	366.1	N. Nakov et al (2013)
9.	IND	human whole blood	liquid-liquid extraction	364.0	Guilherme Araújo Pinto et al (2013)
10.	Diuretics	Dietary supplements	SPE	363.90	J.W. Kim et al (2013)
11.	Compounds	In metabolites	SPE	366.1	Yun Zeng et al (2016)
12.	IND	Human whole blood	SPE	366	Libo Zhao et al (2013)

Nakov, N., and co-authors explored the automated SPE procedure together with fast LC-MS/MS for serum determination of IND. The SPE analyses were performed with the help of polymeric mixed-mode sorbent using the positive mode electrospray technique of ionization [Nakov 2013].

Tang, J. *et al.* have tested LC-ESI-MS detection for analyzing IND in human blood. Consequently, the explored work was efficiently applied to a bioequivalence approach in which 20 healthy volunteers received 3 mg as a single oral dose reference and tested sustained-release IND formulations in an open, two-period, randomized crossover protocol. The test tablets showed relative bioavailability of 110:1 34:5% compared to the reference tablets [Tang 2005].

Chen, W.D. *et al.* investigated LC-ESI-MS approach for the quantification of IND in human plasma. A liquid-liquid extraction protocol was referred to by injecting extracts onto column (C-18) in gradient elution [Chen 2006].

Jain, D.S. *et al.* evaluated the highly precise and sensitive procedure for determining IND in whole human blood with the help of LC-MS/MS. A lower limit of measurement for the method under investigation is a sensitivity of 0.5 ng/mL in the human whole blood specimen.

The protocol adopted for the isolation and extraction of IND includes haemolysis and deprotonation of whole blood. The agent used was using ZnSO₄. The liquid-liquid extraction procedure utilized ethyl acetate as a extracting medium. Post drying sample extracts were reconstituted and analysed using LC-MS/MS, supported with a turbo ion spray (TIS) source [Jain 2006].

Morihisa, H. *et al.* assessed IND in human serum was examined using LC-ESI-MS/MS. Using SPE and Oasis HLB 96-well plates, IND and 4-diethylaminobenzoic acid (internal standard) were concurrently extracted from serum samples and quantified by LC-MS/MS [Morihisa 2008].

Murray, G.J., and Danaceau, J. P. have exhibited two common screening protocols for the assessment of 49 exogenous compounds, including 21 (diuretics) with 19 (beta-blockers) and 8(stimulants) and 2(steroids) compounds simultaneously in human urine as biological fluid by HPLC-MS/MS and UPLC-MS/MS. The samples were extracted using SPE. Samples were injected onto RP-HPLC and UPLC columns and instruments capable of polarity switching. The method was validated as per ISO 17025 international standards.

Sixty urine samples submitted were checked, and the results were correlated with previously validated procedures. Both methods were found to be helpful. The use of UPLCMS/MS allowed reliable screening with significantly less analysis time [Murray 2009].

Woo, H. *et al.* investigated an HPLC and LC-MS/MS protocols for determining 17 (diuretics) from dietary supplements. The chromatographic analysis and resolution were performed under the RP mechanism on the HSS-T3 column. A total of (16) dietary supplements are involved. In all sample analyses, diuretics were not detected [Woo 2013].

Zeng, Y. *et al.* demonstrated that the LC-MS/MS procedure improved product ion (EPI) method. The study analyzed 40 compounds simultaneously with a weight loss effect and included bisacodyl, phenolphthalein, sibutramine, and metabolites [Zeng 2016].

Zhao, L. *et al.* established a distinction between LC-UV and LC-MS/MS for IND. The similar methodology was used for bioequivalence investigations. The criteria used to compare the two approaches were their levels of selectivity, linearity, precision, and limit of quantification. The two approaches have thus far proven to be reliable and compatible. Additionally, the LC-MS/MS methodology was around 25 times more sensitive than the other method while requiring only a quarter of the blood volume. In contrast to the previous method, which required 11 minutes to run each sample, the LC-MS/MS method only required 3.5 minutes. As participants, 40 healthy Chinese men volunteers were chosen. The second half received 1.5 mg IND sustained-release coated pills, while the first half received 2.5 mg IND immediate-release tablets [Zhao 2010].

8. Infrared Spectrophotometry Method

Sirbu, C. *et al.* investigated a NIR-chemometric method to estimate IND as API (Active Pharmaceutical Ingredient). The method also involved the two leading excipients. The components were determined from the pharmaceutical powder used as a blend for manufacturing IND sustained-release (SR) tablets. Calibration models were developed for IND, hydroxyl propyl methylcellulose (HPMC) assay, and lactose. The 25 series of powder blends (prepared according to

an experimental design) were used, and the NIR spectra were recorded. The methods were validated as per ICH regulations. The validation findings depicted good precision, trueness, and accuracy [Sirbu 2014].

8.1. Calorimetric Analysis

Saleh, H.M. *et al.* reported two strategies for IND estimation in bulk and marketed matrix. These approaches mostly focused on IND being oxidised with iron (III) in an acidic solution. As a result of the freed iron (II) reacting with 10-phenanthroline (Method A), the ferroin complex was calorimetrically compared to the reagent blank at lambda max 509 nm. The drug's lowering of Fe (III) is a component of method (B). With 2, 20-bipyridyl, iron (III) forms a colourful complex with a maximum radius of 522 nm [Saleh 2001].

8.2. Kinetic Spectrofluorimetric Method

A simple and precise kinetic spectrofluorimetric approach was published by Guo, Y., and colleagues for simultaneously evaluating sibutramine, IND, and HCTZ in commonly found weight-loss supplements. Cerium (IV) ammonium sulphate that was dissolved in an acidic solution oxidised the analytes. At the excitation wavelength, the kinetic-fluorescence spectrum of the generated cerium (III) was examined between 0 and 600 s of reaction time at 250 nm i.e., excitation wavelength [Guo 2016].

Conclusions

The present review highlights specific typical and atypical methodological approaches to assessing IND in bulk, pharmaceutical, and biological matrices. Thorough literature searches were conducted for HPLC, Bio-analytical, HPTLC, UV/Vis-Spectroscopy, Spectrofluorimetric analysis, TLC-densitometric analysis, LC-MS/MS, etc. for assessment of IND in bulk and its combined pharmaceutical formulations and plasma.

HPLC assisted with UV detection was a highly explored methodology by many authors for estimating IND in bulk and for pharmaceutical formulations. The hyphenated techniques such as LS-MS/MS have been studied to determine IND and its metabolite in plasma and other biological matrices. Also, these techniques were studied for pharmacokinetic as well as bioequivalence studies.

Acknowledgment

We acknowledge our truthful thanks to Z.B. Patil Arts, Science and Commerce College, Deopur, Dhule.

Authorship Contribution

The data collection and manuscript compilation were done by Dr. Aboli P. Edlabadkar.

The Manuscript was edited by Dr. A. P. Rajput.

Funding

The present work is not funded by any funding agency.

Conflict of Interest

The authors do not have any conflict of interest

Declaration

It is an original data and has neither been sent elsewhere nor published anywhere.

References

- Al-Tannak, N. F. (2018). UHPLC-UV method for simultaneous determination of perindopril arginine and indapamide hemihydrate in combined dosage form: a stability-indicating assay method. *Scientia Pharmaceutica*, 86(1), 7.
<https://doi.org/10.3390/scipharm86010007>
- Asmar, R. G., London, G. M., O'Rourke, M. E., Safar, M. E., & REASON Project Coordinators and Investigators. (2001). Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. *Hypertension*, 38(4), 922-926.
<https://doi.org/10.1586/14779072.1.1.43>
- Basu, A., Das, B., Basak, K., Chakraborty, K., & Basu, S. (2011). Development & validation of stability indicating high performance liquid chromatographic method for simultaneous estimation of atenolol & indapamide in tablet dosage form. *Journal of Pharmacy Research*, 4(6), 1677-1680.
- Bataillard, A., Schiavi, P., & Sassard, J. (1999). Pharmacological properties of indapamide. *Clinical pharmacokinetics*, 37(1), 7-12.
<https://doi.org/10.2165/00003088-199937001-00002>
- Bhoir, V., Hibare, V., & Damle, M. C. (2014). Development and validation of stability-indicating HPTLC method for the estimation of perindopril and Indapamide. *International Journal of Pharmacy and Pharmaceutical Sciences*, 6, 621-5.
- British Pharmacopoeia, Vol I. The British Pharmacopoeia Commission, London; 2022. 1313 – 1314.
- Budavari, S., O'Neil, M. J., Smith, A., & Heckelman, P. E. (1996). The Merck index: an encyclopedia of chemicals, drugs, and biologicals. Retrieved from: <https://www.ncbi.nlm.nih.gov/nlmcatalog/9609686>.
- Cârje, A. G., Ion, V., Muntean, D. L., Hancu, G., Balint, A. L. I. N. A., & Imre, S. I. L. V. I. A. (2016). Enantioseparation of indapamide by high performance liquid chromatography using ovomucoid glycoprotein as chiral selector. *Farmacia*, 64, 181-186.
- Cavalieri, L., & Cremonesi, G. (2007). Delapril plus Indapamide. *Clinical drug investigation*, 27(6), 367-380.
<https://doi.org/10.2165/00044011-200727060-00001>
- Chavda, J. M., Raval, M. A., & Dave, K. R. (2012). Simultaneous estimation of Telmisartan and Indapamide in Bulk Drug and in pharmaceutical dosage form using UV-Spectrophotometry. *Pharm Methods*, 5, 4169.
- Chen, W., Liang, Y., Zhang, H., Li, H., Xiong, Y., Wang, G. & Xie, L. (2006). Simple, sensitive and rapid LC – MS method for the quantitation of indapamide in human plasma — application to pharmacokinetic studies. *Journal of Chromatography B*. 842, 58–63.
<https://doi.org/10.1016/j.jchromb.2006.03.024>
- Dawud, E. R., & Shakya, A. K. (2019). HPLC-PDA analysis of ACE-inhibitors, hydrochlorothiazide and indapamide utilizing design of experiments. *Arabian Journal of chemistry*, 12(5), 718-728.
<https://doi.org/10.1016/j.arabjch.2014.10.052>
- Desai, A. K., Chauhan, R. S., Shah, S. A., Shah, D. R. (2012). HPTLC Method for the Simultaneous Estimation of Amlodipine Besylate and Indapamide in Tablet Formulation. *Asian Journal of Research in Chemistry*, 5, 510-514.
- Ding, L., Yang, L., Liu, F., Ju, W., & Xiong, N. (2006). A sensitive LC – ESI-MS method for the determination of indapamide in human plasma : Method and clinical applications. *Journal of pharmaceutical and Biomedical analysis*. 42, 213–217.
<https://doi.org/10.1016/j.jpba.2006.03.039>
- Divitiis, O. D., Somma, S. D., Petitto, M., Fazio, S., & Ligouri, V. (1983). Indapamide and atenolol in the treatment of hypertension: double-blind comparative and combination study. *Current Medical Research and Opinion*, 8(7), 493-500.
<https://doi.org/10.1185/03007998309109788>
- El-Bagary, R. I., Elkady, E. F., Mowaka, S., & Attallah, M. A. (2017). A validated HPLC method for simultaneous determination of perindopril arginine, amlodipine, and indapamide: application in bulk and in different pharmaceutical dosage forms. *Journal of AOAC International*, 100(4), 992-999.
<https://doi.org/10.5740/jaoacint.16-0279>

- El-Gindy, A., Nassar, M. W., Attia, K. A. S., Abu-Seada, H. H., & El-Ghandour, M. (2014). Stability-Indicating HPLC method for simultaneous determination of captopril, indapamide, and their related compounds. *Journal of Liquid Chromatography & Related Technologies*, 37(5), 696-712. <https://doi.org/10.1080/10826076.2012.758138>.
- Erk, N. (2001). Comparison of spectrophotometric and an LC method for the determination perindopril and indapamide in pharmaceutical formulations. *Journal of pharmaceutical and Biomedical Analysis*, 26(1), 43-52. [https://doi.org/10.1016/S0731-7085\(01\)00388-0](https://doi.org/10.1016/S0731-7085(01)00388-0)
- Ernst, M. E., & Fravel, M. A. (2022). Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide. *American Journal of Hypertension*, 35(7), 573–586. <https://doi.org/10.1093/ajh/hpac048>
- Ezzeldin, M. I., Shokry, E., Fouad, M. A., & Elbagary, R. I. (2013). Application of chromatographic and spectrophotometric methods for the analysis of aliskiren and hydrochlorothiazide antihypertensive combination. *International journal of advanced chemistry*, 1(2), 13-20. <https://doi.org/10.14419/ijac.v1i2.1099>
- Fernandes, N., Nimdeo, M. S., Choudhari, V. P., Kulkarni, R. R., Pande, V. V., & Nikalje, A. G. (2008). Dual wavelength and simultaneous equation spectrophotometric methods for estimation of atenolol and indapamide in their combined dosage form. *Int J Chem Sci*, 6(1), 29-35.
- Fernandez-Carballido, A., Barcia, E., Cordoba-Diaz, D., Cordoba-Diaz, M., & Negro, S. (2014). Lisinopril-loaded chitosan nanoparticles and indapamide in hard gelatine capsules: simultaneous HPLC quantification. *Current pharmaceutical Analysis*, 10(1), 10-19. <https://doi.org/10.2174/157341291001140102104350>
- Gao, X., Chen, J., Mei, N., Tao, W., Jiang, W., & Jiang, X. (2005). HPLC Determination and Pharmacokinetic Study of Indapamide in Human Whole Blood. *Chromatographia*. 581–582. <https://doi.org/10.1365/s10337-005-0548-1>
- Gumieniczek, A., Mączka, P., Komsta, Ł., & Pietraś, R. (2015). Dissolution profiles of perindopril and indapamide in their fixed-dose formulations by a new HPLC method and different mathematical approaches. *Acta Pharmaceutica*, 65(3), 235-252. <https://doi.org/10.1515/acph-2015-0024>
- Guo, Y.; Ni, Y., Chen, J., Kokot, S. A. (2016). Kinetic spectrofluorometric method, aided by chemometrics, for the analysis of Sibutramine, Indapamide and hydrochlorothiazide compounds found in weight-reducing tonic samples. *Analytical Methods*, 8, 197-204. <https://doi.org/10.1039/C5AY02191J>
- Hegheş, S. C., Rus, L. M., Rus, L. L., Bojiţă, M. T., & Iuga, C. A. (2017). HPLC-UV determination of indapamide in the presence of its main synthesis and degradation impurities. Method validation. *Farmacia*, 65(5), 755-760. <https://doi.org/10.1016/j.jchromb.2009.09.036>
- Indian Pharmacopoeia. Vol. II. The Indian pharmacopoeia commission. Central Indian Pharmacopoeia Laboratory, Ministry of Health and Family Welfare, Govt of India, Sector. 2018, 2283-2287
- Jadhav, U., Hiremath, J., Namjoshi, D. J., Gujral, V. K., Tripathi, K. K., Siraj, M., ... & Safar, M. (2014). Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. *PLoS one*, 9(4), e92955. <https://doi.org/10.1371/journal.pone.0092955>
- Jain, D. S., Subbaiah, G., Sanyal, M., Pande, U. C.; & Shrivastav, P. (2006). Liquid chromatography – tandem mass spectrometry validated method for the estimation of indapamide in human whole blood. *Journal of Chromatography B*. 834, 149–154. <https://doi.org/10.1016/j.jchromb.2006.02.040>
- Kadian, N., Maste, M., Bhat, A. R., Pujari, P., Ramesh, V., & Bhatt, A. R. (2012). An Effective RP-HPLC Method for the Simultaneous Determination of Atenolol and Indapamide in Marketed Tablet Formulation (ATEN-D). *Asian Journal of Research In Chemistry*, 5(3), 405-408.
- Karunakar, N., Puranik, S. B., Kumar, G. V. S., Masood, M. D., Sridhar, K. A. (2012). Development and Validation of RP-HPLC Method for Simultaneous Estimation of Amlodipine and Indapamide in Bulk and Tablet Dosage Form. *Asian Journal of Biomedical and Pharmaceutical Sciences*, 2(12), 55-59.
- Madhavi, K., Deepti, K., & Harika, B. (2014). RP-HPLC Method Development and Validation for the Simultaneous Estimation of Atenolol and Indapamide in Pharmaceutical Tablet Dosage Form. *International Journal of Pharmacy and Analytical Research*, 3, 109–117.
- Mahant, B. D., Rajoriya, V., Jain, R. K., & Kashaw, V. (2016). UV-Spectrophotometric and Stability Indicating RP-HPLC Method for the Simultaneous Estimation of Amlodipine Besylate and Indapamide. *Analytical Chemistry Letters*, 6(4), 354-370. <https://doi.org/10.1080/22297928.2016.1217787>
- Miller, R. B., Dadgar, D., & Lalande, M. (1993). High-performance liquid chromatographic method for the determination of indapamide in human whole blood.

Journal of Chromatography B: Biomedical Sciences and Applications, 614(2), 293-298.

[https://doi.org/10.1016/0378-4347\(93\)80321-T](https://doi.org/10.1016/0378-4347(93)80321-T)

- Modi, D. K., & Patel, C. N. (2011). Development and Validation of Spectrophotometric Method for Simultaneous Estimation of Perindopril and Indapamide in Combined. *Journal of AOAC International*, 6, 46–52.
- Morihisa, H., Fukata, F., Muro, H., Nishimura, K., & Makino, T. (2008). Determination of indapamide in human serum using 96-well solid-phase extraction and high-performance liquid chromatography – tandem mass spectrometry (LC – MS / MS). *Journal of chromatography*, B.870, 126–130.
<https://doi.org/10.1016/j.jchromb.2008.05.042>
- Murray, G. J., & Danaceau, J. P. (2009). Simultaneous extraction and screening of diuretics, beta-blockers, selected stimulants and steroids in human urine by HPLC-MS / MS and UPLC-MS / MS. *Journal of Chromatography B*, 877, 3857–3864.
- Nakov, N., Mladenovska, K., Labacevski, N., Dimovski, A., Petkovska, R., Dimitrovska, A., & Kavrovski, Z. (2013). Development and validation of automated SPE-LC-MS / MS method for determination of indapamide in human whole blood and its application to real study samples. *Biomedical Chromatography*, 27, 1540–1546. <https://doi.org/10.1002/bmc.2957>
- Nakov, N., Mladenovska, K., Zafirov, D., Dimovski, A., Petkovska, R., Dimitrovska, A. & Kavrovski, Z. (2013). High-throughput SPE-LC-MS / MS method for determination of indapamide in human serum. *Macedonian Pharmaceutical Association*, 59, 15–22.
<https://doi.org/10.33320/maced.pharm.bull.2013.59.002>
- Nazareth, C., Shivakumar, B., Reddy, P., Gurupadayya, B. M. (2013). Development and validation of HPTLC method for simultaneous analysis of olmesartan and indapamide in bulk drug and combined tablet formulation, *Indo American Journal of Pharmaceutical Research*, 3,(12) 1709-1715.
- Ozden, T., TURKER, Z. H., & Tosun, A. U. (1998). Quantitative High-performance Liquid Chromatographic Analysis of Indapamide in Pharmaceutical Dosage Forms. *Pharmacy and Pharmacology Communications*, 4(8), 397-399.
- Pai, J. B., Shetty, A. S. K., & Gopinath, B. (2011). Development and Validation of RP-HPLC Method for Quantitative estimation of Indapamide in Bulk and Pharmaceutical dosage forms. *International Journal of pharmtech Research*, 3, 1482–1487.
- Pai, J. B., Shetty, S., Chenna, G., Gopinath, B., & Ahmed, M. (2011). Development of new spectrophotometric methods for the determination of Indapamide in bulk and pharmaceutical formulations. *International Journal of ChemTech Research*, 3(2), 755-760.
- Parusu, T., & Ponneri, V. (2012). RP-HPLC method for simultaneous determination of atenolol and indapamide in pharmaceutical dosage forms, human blood and milk. *European Journal of chemistry*, 3(2), 138-142.
<https://doi.org/10.5155/eurjchem.3.2.138-142.537>
- Patel, D. B., Mehta, F. A., & Bhatt, K. K. (2012). Simultaneous estimation of amlodipine besylate and indapamide in a pharmaceutical formulation by a high performance liquid chromatographic (RP-HPLC) method. *Scientia Pharmaceutica*, 80(3), 581-590.
<https://doi.org/10.3797/scipharm.1203-07>
- Patel, N. M., Raval, M. A., Shah, K. A. (2013). Development of Stability Indicating HPTLC Method For Simultaneous Estimation Of Telmisartan And Indapamide In Bulk Drug And Pharmaceutical Dosage Form, *International Journal of Pharmtech Reserach*, 5(4), 1546–1553.
- Patel, P. K., Parmar, R. R., Shah, V. N., & Shah, D. A. (2012). Simultaneous estimation of telmisartan and indapamide in pharmaceutical dosage form by UV spectrophotometric method. *International Journal of Institutional Pharmacy and Life Sciences*, 2, 50–57.
- Pathak, A. K., Lodhi, R., & Shikhri, M. K. (2011). A selective reverse phase HPLC method for simultaneous determination of perindopril and indapamide in solid dosage form and bulk drug. *J. Pharm. Res*, 4(8), 2512-2513.
- Pinto, G. A., Pastre, K. I., Bellorio, K. B., de Souza Teixeira L, de Souza W. C., de Abreu F. C., de Santana e Silva Cardoso F. F., Pianetti G. A., César I. C. (2014). An improved LC-MS/MS method for quantitation of indapamide in whole blood: application for a bioequivalence study. *Biomedical Chromatography*, 28 (9), 1212-8. <https://doi.org/10.1002/bmc.3148>
- Raj, M. C., Chaudhari, B. G. (2012). Development and Validation of RP-HPLC Method for Simultaneous Estimation of Amlodipine Besylate and Indapamide in Tablet Dosage Form. *International Journal of Pharmaceutical Science and Research*, 3(9), 3146-3150.
<https://doi.org/10.7324/JAPS.2012.2911>
- Rani, G. T., Sankar, D. G., Kadgpathi, P., & Satyanarayana, B. (2011). A validated RP-HPLC method for simultaneous estimation of atenolol and indapamide in pharmaceutical formulations. *E-Journal of chemistry*, 8(3), 1238-1245.
<https://doi.org/10.1155/2011/121420>
- Rao, J. R. (2011). Simultaneous HPTLC analysis of atenolol and indapamide in tablet formulation *Int J Compr Pharm*, 9, 1-4.

- Saleh H. M., Amin A. S., El-Mammli M. (2001). New colorimetric methods for the determination of indapamide and its formulations. *Microchimica Acta*, 1,137(3-4):185-189.
<https://doi.org/10.1007/s006040170010>
- Saujanya S. (2017) Method Development and Validation of Simultaneous Estimation of Perindopril and Indapamide in Tablet By RP-HPLC Method, *Indo American Journal of Pharmaceutical Research*, 7(9), 390-397
- Shah, R. N., Gandhi, D. B., & Patel, M. M. (2012). RP-HPLC method for simultaneous estimation of Amlodipine Besylate and Indapamide in tablet dosage form. *Asian Journal of Research in Chemistry*, 5(5), 8.
- Shah, R. N., Gandhi, D. B., & Patel, M. M. (2012). Simultaneous determination of Amlodipine Besylate and Indapamide in tablet dosage form by Absorption correction method and First order derivative UV spectroscopy. *Int J PharmTech Res*, 4(3), 1018-24.
- Sheth, A., Patel, K. N., Badmanaban, R., Doshi, N., & Shah, N. (2013). Simultaneous estimation of olmesartanmedoxomil and indapamide from bulk and commercial products using a validated reverse phase high performance liquid chromatographic technique. *Chronicles of young scientists*, 4(1).
[https://doi.org/10.1016/0378-4347\(93\)80321-T](https://doi.org/10.1016/0378-4347(93)80321-T)
- Singhvi, I., Goyal, A. (2007). Visible Spectrophotometric Estimation of Aceclofenac and Indapamide from Tablets using Tablets Folin-Ciocalteu Reagent. *Indian Journal of Pharmaceutical Sciences*. 69(1), 164-165.
<https://doi.org/10.4103/0250-474X.32140>
- Sirbu, C., Tomuta, I., Achim, M., Rus, L., Vonica, L., & Dinte, E. (2014). Quantitative characterization of powder blends for tablets with indapamide by near-infrared spectroscopy and chemometry. *Farmacia*, 62, 48-57.
- Suo, X., Deng, Y., & Hao, A. (2005). Determination of lauroyl-indapamide in rat whole blood by high-performance liquid chromatography. *Journal of Chromatography B*, 819(1), 191-196.
<https://doi.org/10.1016/j.jchromb.2005.01.032>
- Süslü, I., Altınöz, S. (2002). Two derivative spectrophotometric determinations of indapamide in pharmaceutical dosage forms. *Journal of pharmaceutical and biomedical analysis*, 30(2), 357-364.
[https://doi.org/10.1016/S0731-7085\(02\)00328-X](https://doi.org/10.1016/S0731-7085(02)00328-X)
- Tang, J. Li, J. Sun, J. Yin, J. & He, Z. (2005). Rapid and sensitive determination of indapamide in human blood by liquid chromatography with electrospray ionization mass spectrometric detection: application to a bioequivalence study, *Die Pharmazie-An International Journal of Pharmaceutical Sciences*, 60, 819-822.
- Tarkase, K. N., Jadhav M. B., Tajane S. R., Dongare U. S. (2012) Development and Validation of UV-Spectrophotometric methods for estimation of Indapamide in bulk and tablet dosage form. *Der Pharma Chemica*, 4(3), 1128-1132.
- The United State Pharmacopoeia, USP41-NF36, United State Pharmacopoeial Convention, Inc., Rockville MD 2018. 2139-40.
- Valentin, I., Silvia, I., Gabriela, C. A., & Lucia, M. D. (2015). Analytical Performance of an HPLC and CZE Methods for the Analysis and Separation of Perindopril Erbumine and Indapamide. *Acta Marisiensis-Seria Medica*, 61(4), 324-327.
<https://doi.org/10.1515/amma-2015-0073>
- Vyas, N., Panchal, S. (2012). A Validated HPTLC Method for Simultaneous Estimation of Nebivolol and Indapamide in Solid Dosage Form. *Asian Journal of Pharmaceutical and Clinical Research*, 5(4), 215-2018.
- Waeber, B. (2003). Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. *Expert Review of Cardiovascular Therapy*, 1(1), 43-50.
<https://doi.org/10.1586/14779072.1.1.43>
- Woo H., Kim J. W., Han K. M., Lee J. H., Hwang I. S., Lee J. H., Kim J., Kweon S. J., Cho S., Chae K. R., Han S. Y. (2013). Simultaneous analysis of 17 diuretics in dietary supplements by HPLC and LC-MS / MS. *Food Additives & Contaminants: Part A*, 30(2), 209-217.
<https://doi.org/10.1080/19440049.2012.738939>
- Zeng, Y., Xu, Y., Kee, C., Low, M., & Ge, X. (2016). Analysis of 40 weight loss compounds adulterated in health supplements by liquid chromatography quadrupole linear ion trap mass spectrometry. *Drug testing and analysis*, 8, 351-356.
<https://doi.org/10.1002/dta.1846>
- Zhao L., Gu S, Xu R., Cui X., Gan F., Chen H. (2010). Comparison of liquid chromatography-ultraviolet and chromatography-tandem mass spectrometry for the determination of indapamide in human whole blood and their applications in bioequivalence studies. *Drug Research*, 60(07), 432-439.
<https://doi.org/10.1055/s-0031-1296308>



Journal of Pharmaceutical Technology, Research and Management

Chitkara University, Saraswati Kendra, SCO 160-161, Sector 9-C,
Chandigarh, 160009, India

Volume 10, Issue 1

May 2022

ISSN 2321-2217

Copyright: [©2022 A. P. Rajput and A. P. Edlabadkar] This is an Open Access article published in Journal of Pharmaceutical Technology, Research and Management (J. Pharm. Tech. Res. Management) by Chitkara University Publications. It is published with a Creative Commons Attribution- CC-BY 4.0 International License. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.